Regeneron Pharmaceuticals (REGN) News Today

Regeneron Pharmaceuticals, Inc. (REGN) saw its stock react to Q2 earnings and clinical updates after the company reported strong growth in key franchises and mixed regulatory news.

• Positive Sentiment: Robust Q2 results exceeded revenue and EPS estimates, driven by Dupixent and Libtayo growth offsetting Eylea declines, and management highlighted an expanding obesity pipeline for long-term growth. Regeneron: Rapidly Decreasing Importance Of Eylea
• Positive Sentiment: Regeneron topped Wall Street estimates for Q2 revenue and profit on strong Dupixent demand, lifting shares nearly 3% in pre-market trading. Regeneron beats second-quarter results estimates on Dupixent sales boost
• Positive Sentiment: Zacks reports REGN beat Q2 EPS and revenue consensus, with Eylea HD and Dupixent sales up, contributing to upward momentum in the stock. Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
• Positive Sentiment: Phase 3 lymphoma trials showed promising early results, offering potential new treatment avenues and bolstering long-term growth prospects. Regeneron’s Phase 3 Trial: A New Hope for Lymphoma Treatment
• Positive Sentiment: Another follicular lymphoma Phase 3 trial update reinforced the potential for a game-changing therapy in blood cancers. Regeneron’s Promising Phase 3 Trial for Follicular Lymphoma: A Potential Game Changer?
• Neutral Sentiment: The Q2 earnings call transcript highlighted cost management and tariff impacts were downplayed, providing more detail on operational performance. Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
• Neutral Sentiment: Regulatory rating agencies maintained a “Moderate Buy” consensus for REGN, reflecting steady analyst confidence in the stock. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Recommendation of "Moderate Buy"
• Negative Sentiment: The FDA declined to approve Regeneron’s blood cancer therapy for a second time due to manufacturing site inspection issues, posing a setback to oncology pipeline momentum. US FDA declines to approve Regeneron's blood cancer therapy for second time
• Negative Sentiment: Production delays at a key third-party manufacturing partner (Catalent) may pressure pipeline timelines, although management remains confident in near-term priorities. Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines

Overall, positive earnings and promising trial data have supported an uptick in REGN shares, while regulatory setbacks and supply-chain hiccups introduce near-term headwinds.